[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Anders Aneman\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":48},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100568358","fibrinolysis-resistance-in-infection-and-trauma-100568358",false,"NCT06680180","Fibrinolysis Resistance in Infection and Trauma","FORTITUDE","Sepsis\u002FSeptic shock Inclusion Criteria:\n\n* Admission to ICU, needing at least one organ supportand principally for the management of clinically suspected Sepsis or Septic shock according to Spesis-3 criteria (including SARS-COV-2)\n* Expected to remain in ICU and survive beyond the day after tomorrow\n\nSepsis Exclusion Criteria:\n\n* On oral anticoagulant\u002Fantiplatelet therapy\n* Not for full, active ICU support\n* Death is deemed inevitable within 24 hrs\n\nTrauma Inclusion Criteria:\n\n* Trauma is the principal diagnosis on ICU admission\n* Expected to remain in ICU and survive beyond the day after tomorrow\n* Receiving respiratory support at the time of ICU admission - high-flow nasal prongs, non-invasive or invasive ventilation\n* Already received, or considered at risk of needing a blood product transfusion within 24 hrs of injury\n\nTrauma Exclusion Criteria:\n\n* Nursing home resident\n* Unsurvivable head injury\n* Not for full, active ICU support\n* Death is deemed inevitable within 24 hrs",true,"ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","15 Days","OBSERVATIONAL","Blood coagulation disorders are often seen in critically ill patients e.g. with severe infection or following extensive injury, that can lead to life threatening events as a result of excessive blood clot formation leading to organ failure. This study aims to use Viscoelastic Testing (VET) technology to detect patients at risk of excessive blood blot formation at the bedside, test new blood coagulation drugs, and guide life-saving use of blood modifying treatments.",[26,27],"Sepsis and Septic Shock","Trauma",[29,30,27,31,32,33,34],"Viscoelastic testing (VET)","Sepsis","Fibrinolytic Agents","Fibrin Modulating Agents","Tissue Plasminogen Activator","Plasminogen","RECRUITING","2024-11-06",{"date":38,"type":39},"2024-11-08","ACTUAL",{"date":41,"type":39},"2024-06-01",{"date":43,"type":21},"2026-06-01",{"name":45,"class":46},"Anders Aneman","OTHER",4,""]